Pharming Group N.V.

Pharming Group N.V. is a global biotechnology company that develops and commercializes innovative therapies for rare and ultra-rare diseases with significant unmet need. The company focuses on immunological and genetic conditions. Pharming Group N.V. was incorporated as a private company with limited liability under the laws of the Netherlands on November 11, 1988, under the name GENFARM B.V. On May 29, 1997, it converted into a public company named Pharming Holding N.V., and effective July 2, 1998, it was renamed Pharming Group N.V. The company is registered with the Dutch Chamber of Commerce under number 28048592. Its ordinary shares are traded on Euronext Amsterdam under the symbol "PHARM." As of December 22, 2020, its ADSs were admitted for listing on the Nasdaq under the symbol "PHAR" and began trading on Nasdaq Global Market. The registered office is located at Darwinweg 24, 2333 CR Leiden, the Netherlands. The company's actual capital expenditures for the years ended December 31, 2025, 2024, and 2023 amounted to $0.7 million, $0.8 million, and $1.4 million, respectively. These capital expenditures primarily consist of property, plant, and equipment, such as investments in new machinery and equipment in the Netherlands.